PharmaCyte Biotech (PMCB) Receivables - Net (2011 - 2025)
PharmaCyte Biotech (PMCB) posted quarterly Receivables - Net of $3.4 million for Q1 2025, up 21.81% quarter-over-quarter from $2.8 million in Q2 2024.
PharmaCyte Biotech (PMCB) Receivables - Net (2011 - 2025) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Receivables - Net for 4 consecutive years, with $3.4 million the latest figure, recorded in Q1 2025.
- In Q1 2025, Receivables - Net changed N/A year-over-year to $3.4 million; the TTM figure through Jan 2025 stood at $3.4 million (changed N/A YoY), while the FY2024 annual figure was $2.8 million, changed N/A from the prior year.
- Receivables - Net rose to $3.4 million in Q1 2025 per PMCB's latest filing, from $2.8 million in the prior quarter.
- Across five years, Receivables - Net topped out at $3.4 million in Q1 2025 and bottomed at $2.8 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | PharmaCyte Biotech | 4.38 Mn | 4.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2025 | 3.36 Mn |
| Jan 31, 2025 | 3.36 Mn |
| Apr 30, 2024 | 2.76 Mn |
| Apr 30, 2024 | 2.76 Mn |
| Apr 30, 2012 | 2,581.00 |
| Apr 30, 2012 | 2,581.00 |
| Jan 31, 2012 | 19,579.00 |
| Jan 31, 2012 | 19,579.00 |
| Oct 31, 2011 | 8,962.00 |
| Oct 31, 2011 | 8,962.00 |
| Jul 31, 2011 | 8,607.00 |
| Jul 31, 2011 | 8,607.00 |
| Apr 30, 2011 | 2,316.00 |
| Apr 30, 2011 | 2,316.00 |